jain.com

Convertible notes offering - $5 billion

Company: Nebius

Subject kind
financing
Statement date
2026-08-24
Promised by
2026-08-24
Promised amount
5000000000.0 USD
Current status
not yet verifiable

The claim, verbatim

Nebius issued $5 billion of convertible senior notes with net proceeds of approximately $4.94 billion, consisting of $3 billion due 2030 at 0.5% coupon and $2 billion due 2034 at 4.5% coupon

Source (primary)

Nebius Group Falls 4% as $5B Convertible Settles, Datadog Drops 3%, Cloudflare Slips - Yahoo Finance (-, news_article)
View cached copy (2026-09-01)Live source ↗

Quote: “Nebius Group priced $5 billion of convertible senior notes with net proceeds of roughly $4.94 billion, and the notes are expected to settle today. The deal came in two tranches: $3 billion due 2030 carrying a 0.5% coupon and convertible at $313.46 per share, and $2 billion due 2034 carrying a 4.5% coupon and convertible at $324.65.”

How we checked this

This claim has not yet been checked assertion-by-assertion against its source. It carries a cited source and quote, but the deeper check has not run. When it does, the result appears here whatever it says.

Additional evidence

confirms Nebius Group Falls 4% as $5B Convertible Settles, Datadog Drops 3%, Cloudflare Slips - Yahoo Finance

Quote: “Nebius Group priced $5 billion of convertible senior notes with net proceeds of roughly $4.94 billion, and the notes are expected to settle today. The deal came in two tranches: $3 billion due 2030 carrying a 0.5% coupon and convertible at $313.46 per share, and $2 billion due 2034 carrying a 4.5% coupon and convertible at $324.65.”

View cached copy (2026-09-01)Live source ↗

Record of changes

September 4, 2026 — stated
Automated extraction from the cited source. Recorded automatically from the cited source when it was published, then queued for evidence review.
September 4, 2026 — not yet verifiable
Automated extraction from the cited source. Recorded automatically from the cited source when it was published, then queued for evidence review.